What is Avantor's gross profit margin?

What is the revenue and EPS growth rate for Avantor year over year?

What factors drove the changes in Avantor's revenue and profit?

What is Avantor's latest dividend and current dividend yield?

What does Avantor do and what are its main business segments?

What guidance did Avantor's management provide for the next earnings period?

Did Avantor beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Avantor next quarter?

- **2026 Transition Year**: Organic revenue growth -2.5% to -0.5%, adjusted EPS $0.77-$0.83.
- **Investments**: $35M in e-commerce and operations, self-funded through cost savings.
- **Segment Focus**: VWR expected to outpace Bioscience and Medtech Products due to challenging comps.
- **End Market Outlook**: Biopharma stable, cautious on education/government sectors.
- **Free Cash Flow**: Target $500-550M, prioritizing debt reduction.

**【CEO Summary Section】**
- Introduced the Avantor Revival program with 5 pillars: go-to-market strategy, operations, portfolio optimization, process simplification, and talent.
- Reorganized into 2 business units: VWR Distribution and Services (product-agnostic channel) and Bioscience and Medtech Products (channel-agnostic products).
- Committed $10-15M in 2026 to upgrade VWR e-commerce platform and $20M in operational investments.
- Emphasized 2026 as a transition year with focus on sustainable top-line growth and margin improvement.
- Noted cautious optimism in biopharma end markets but challenges in education and government sectors.

**【CFO Financial Commentary】**
- Q4 2025: Organic revenue down 4%, adjusted EBITDA $252M, free cash flow $117M.
- Full year 2025: Organic revenue down 3%, adjusted EBITDA $1.069B (16.3% margin).
- 2026 guidance: Organic revenue growth -2.5% to -0.5%, adjusted EPS $0.77-$0.83.
- Margin contraction expected due to mix shifts, investments, and price/cost spread.
- Free cash flow target $500-550M, with debt reduction as top priority.

**【Q&A Highlights】**
- VWR expected to outpace Bioscience and Medtech Products growth in 2026 due to difficult comps in latter segment.
- 2026 investments (~$35M in e-commerce and operations) will be self-funded through cost savings.
- Q1 2026 EPS guidance $0.15-$0.16, with phasing improvements in latter half of the year.
- Emphasis on customer-centric go-to-market strategy to clarify brand identities (VWR, J.T. Baker, Masterflex).

Avantor, Inc. (AVTR) Q4 2025 Earnings Call Transcript

- **Strategic Reset Launched**: CEO unveils 'Avantor Revival' with 5 pillars to address operational inefficiencies, including new leadership hires and $500M share buyback.
- **Q3 Results Miss Expectations**: Revenue down 5% YoY, Adjusted EPS $0.22 (-16% YoY), driven by lab and bioscience underperformance.
- **Key Risks**: Ongoing lab share loss, bioprocessing plant downtime, and U.S. government shutdown impacting academic demand.
- **Long-Term Confidence**: Management commits to simplifying operations, improving service levels, and leveraging brand equity to regain market share.

**【CEO Summary Section】**
- **Avantor Revival Strategy**: CEO Emmanuel Ligner introduced a 5-pillar plan to address operational inefficiencies, including go-to-market strategy overhaul, strategic investments in manufacturing, portfolio focus, cost savings, and talent strengthening. 
- **New Leadership Hires**: Appointment of a Chief Operating Officer, Chief Digital Officer, and Quality & Regulatory Executive to drive operational excellence and digital transformation.
- **Market Challenges**: Acknowledged share loss in lab services but highlighted recent contract wins with 15 global pharma customers, expected to contribute $100M in 2026.

**【CFO Financial Commentary】**
- **Q3 2025 Results**: Revenue $1.62B (-5% YoY), Adjusted EBITDA $268M (16.5% margin), Adjusted EPS $0.22 (-16% YoY). Lab Solutions down 5% YoY, Bioscience Production down 4% YoY.
- **Margin Pressures**: Gross margin decline to 32.4% due to pricing actions in lab. Operating expenses reduced 5% YoY through cost control.
- **Share Repurchase Program**: $500M authorized to capitalize on undervalued shares, alongside debt reduction to 3.1x net leverage.

**【Q&A Highlights】**
- **Lab Market Dynamics**: CFO noted price vs. COGS inflation impacting margins, with plans to improve e-commerce and service levels. Q4 lab revenue expected to decline mid-single digits.
- **Bioprocessing Challenges**: Order backlog reduction stalled, with Q4 process chemicals down double digits YoY. Investment in plant upgrades and S&OP processes underway.
- **Government Shutdown Impact**: Academic and government segment expected to remain weak, with Q4 lab services down mid-single digits.
- **Share Repurchase Rationale**: CEO emphasized confidence in long-term value despite near-term challenges, with buybacks to demonstrate commitment to shareholders.


Avantor, Inc. (AVTR) Q3 2025 Earnings Call Transcript

- **Leadership Transition**: Michael Stubblefield steps down as CEO, with Emmanuel Ligner set to lead starting August 18.
- **Q2 Results**: Flat organic revenue, 16.6% EBITDA margin, $125M free cash flow. Lab Solutions saw $100M share gains but margin pressure from pricing.
- **Bioprocessing Challenges**: Flat YoY growth due to customer headwinds and maintenance; Q3 organic growth -4% to -2%.
- **Guidance Update**: Full-year organic growth revised to -2% to flat; adjusted EPS $0.94-$0.98.
- **Strategic Initiatives**: Digital platform enhancements and cost transformation program on track for $400M savings by 2027.

**【Management Opening Remarks】**
- Michael Stubblefield announced his transition to Executive Chairman, with Emmanuel Ligner set to become CEO on August 18. Stubblefield reflected on 11 years of leadership, highlighting achievements like the VWR acquisition and navigating the COVID-19 pandemic.

**【CEO Commentary】**
- **Q2 Results Overview**: Organic revenue growth was flat year-over-year, with adjusted EBITDA margin at 16.6% and free cash flow of $125 million. The company remains on track for $400 million in cost savings by 2027.
- **Lab Solutions**: Sequential growth of 2% but down 1% YoY. Key wins included $100 million in share gains from contract extensions, offsetting margin pressure from pricing actions. Digital initiatives like Avantor Navigator and a unified buying platform are driving customer engagement.
- **Bioscience Production Challenges**: Bioprocessing revenue flat YoY due to customer headwinds (e.g., gene therapy setbacks) and extended maintenance at a manufacturing facility. Margins were negatively impacted by underabsorption and supply chain costs. Bioscience Production segment margin was 24.9%, down 100 basis points YoY.

**【CFO Financial Commentary】**
- **Q2 Financials**: Reported revenue $1.68B, flat YoY. Adjusted EBITDA $280M (16.6% margin). Adjusted EPS $0.24, down $0.01 YoY. Free cash flow $125M, with 100% conversion of adjusted net income.
- **Guidance Update**: Full-year organic revenue growth revised to -2% to flat (vs. prior -1% to +1%). Adjusted EBITDA margin expected 16.5%-17%, and EPS $0.94-$0.98. Q3 organic growth -4% to -2% due to lab and bioprocessing headwinds.
- **Free Cash Flow Impact**: Reduced to $550M-$600M due to prepaid rebates from new lab contracts.

**【Q&A Key Highlights】**
- **Q3 Guidance**: Brent Jones explained Q3 organic decline reflects continued lab pricing actions and bioprocessing headwinds. Margins expected lower in Q3 due to volume underabsorption.
- **Bioprocessing Outlook**: Michael Stubblefield emphasized strong underlying demand for mAbs platform but acknowledged near-term headwinds. Actions include optimizing supply chain, increasing field intensity, and expanding product offerings.
- **Lab Margin Cadence**: Brent Jones noted margin pressure from pricing actions will persist, but long-term margin expansion is achievable as share gains materialize and absorption improves.
- **Free Cash Flow Concerns**: Michael Stubblefield clarified new contracts do not involve channel stuffing but rather upfront rebates for share gains, which will benefit future periods.


Avantor, Inc. (AVTR) Q2 2025 Earnings Call Transcript

- **Revenue Underperformance**: Lab Solutions down 3% YoY due to U.S. education funding cuts and biotech funding decline. Bioscience Production flat YoY, constrained by controlled environment consumables demand.
- **Cost Efficiency**: $21M SG&A savings in Q1; expanded cost transformation to $400M run rate by 2027.
- **Strategic Initiatives**: AI e-commerce platform launch, delivery excellence program, and $400M cost savings target to drive long-term growth.
- **Tariff Mitigation**: 2% China COGS exposure; no material impact assumed in guidance.

**【CEO Summary Section】**
- **Revenue Performance**: Organic revenue declined 2% YoY due to underperformance in Lab Solutions and Bioscience Production. Lab Solutions faced challenges from U.S. education and government funding uncertainty, while Bioscience Production saw weaker demand for controlled environment consumables.
- **Strategic Actions**: 
  - Appointed Corey Walker as President of Lab Solutions to drive growth and retention of key accounts.
  - Launched delivery excellence initiative to improve supply chain efficiency and customer service.
  - Rolled out AI-enabled e-commerce platform to streamline customer experience.
  - Expanded cost transformation initiative to target $400 million in run rate savings by 2027.
- **Guidance Update**: Full-year organic revenue growth revised to -1% to +1%, reflecting macro headwinds and competitive intensity. Q2 expected to be flat to modestly up YoY.

**【CFO Financial Commentary】**
- **Q1 Financials**: 
  - Adjusted EBITDA of $270 million (17% margin), consistent with expectations.
  - Adjusted EPS of $0.23, in line with plan.
  - Free cash flow of $82 million, impacted by working capital timing.
- **Cost Transformation**: 
  - Generated $21 million in SG&A savings, contributing to 7% YoY decline.
  - Expanded initiative to target $400 million in run rate savings by 2027.
- **Tariff Exposure**: 2% COGS exposure to China, with plans to mitigate through alternate sourcing and customer collaboration.

**【Q&A Highlights】**
- **Lab Solutions Challenges**: U.S. higher education funding cuts and biotech funding decline (40% QoQ) drove 3% YoY decline. Competitive intensity led to volume losses at key accounts.
- **Bioscience Production**: Bioprocessing order book strong, but controlled environment consumables demand weak due to macro cost controls. Mid-single-digit growth expected for 2025.
- **Tariff Mitigation**: No material impact assumed in guidance; leveraging global supply chain and customer collaboration to offset potential surcharges.
- **Cost Front-Loading**: Incremental $75 million in 2025 savings to be front-loaded, enhancing operational flexibility in uncertain environment.

Avantor (AVTR)-25 Apr 25-2025 Q1 Earnings call transcript

- **Strong Q4 Performance**: 1% organic growth, 18.2% EBITDA margin, $222M free cash flow, and $1.3B debt reduction in 2024.
- **2025 Growth Drivers**: Bioprocessing (mid- to high single-digit growth), lab solutions (low single-digit), and 18-19% EBITDA margin target.
- **Debt Reduction Focus**: Targeting <3x net leverage, with $1.3B debt paid in 2024 and $750M in Q4.
- **Cost Savings Impact**: $130M in-year savings in 2024, aiming for $250M+ run rate by end-2025.
- **Bioprocessing Resilience**: 4Q order intake growth, 2-3-month lead times, and mid- to high single-digit Q1 guidance.


**【CEO Summary Section】**
- **Revenue Growth and Market Recovery**: Q4 revenue of $1.69 billion with 1% organic growth, driven by bioprocessing segment (high single-digit growth). Lab Solutions showed resilience amid macro challenges.
- **Financial Highlights**: Adjusted EBITDA of $308 million (18.2% margin), free cash flow of $222 million, and $1.3 billion debt reduction in 2024, lowering net leverage to 3.2x.
- **2025 Outlook**: Guiding for 1-3% organic revenue growth, 18-19% EBITDA margin, and double-digit EPS growth. Focus on bioprocessing (mid- to high single-digit growth) and lab solutions (low single-digit growth).
- **Strategic Initiatives**: Cost transformation saving $130 million in 2024, targeting $250 million+ run rate by end-2025. Expansion of services like virtual lab assistance and manufacturing capacity in Poland.

**【CFO Financial Commentary】**
- **Q4 Financials**: GAAP net income $420M, Non-GAAP EPS $0.27 (up $0.02 YoY). Free cash flow conversion >115%, debt paydown of $750M in Q4.
- **2025 Guidance**: 
  - **Revenue**: Reported decline of -3% to -1% (including 2% FX and clinical services headwinds).
  - **Margins**: EBITDA margin 18-19%, targeting 20% by end-2025 with cost savings and end-market recovery.
  - **EPS**: $1.02-$1.10 (10% growth midpoint), driven by deleveraging and interest expense reduction.
  - **Cash Flow**: $650-700M free cash flow, supporting further debt reduction.

**【Q&A Key Themes】**
- **Bioprocessing Momentum**: 4Q order intake growth, 2-3-month lead times, and mid- to high single-digit Q1 guidance. Long-term confidence in double-digit growth potential.
- **Lab Business Challenges**: Muted seasonal trends, but margin expansion (13.1% Q4) from cost savings and mix improvement. Expect low single-digit growth in 2025.
- **Policy Risks**: Limited direct exposure to NIH funding, but monitoring academic/government spending impacts.
- **M&A Strategy**: Focus on deleveraging to <3x net leverage, but open to selective opportunities post-2025.


Actual				0.17	0.19	0.24	0.29	0.35	0.35	0.35	0.36	0.38	0.37	0.34	0.32	0.29	0.28	0.25	0.25	0.22	0.25	0.26	0.27	0.23	0.24	0.22	0.22
Forecast				0.1474	0.1432	0.2069	0.2604	0.2766	0.3083	0.3192	0.3331	0.3547	0.3761	0.3321	0.3022	0.2856	0.293	0.2511	0.2232	0.201	0.2324	0.2546	0.2573	0.2314	0.2482	0.2248	0.219
Surprise	0.00%	0.00%	0.00%	+15.33%	+32.68%	+16.00%	+11.37%	+26.54%	+13.53%	+9.65%	+8.08%	+7.13%	-1.62%	+2.38%	+5.89%	+1.54%	-4.44%	-0.44%	+12.01%	+9.45%	+7.57%	+2.12%	+4.94%	-0.61%	-3.30%	-2.14%	+0.46%

AVTR

AVTR fundamentals

AVTR Q4 2025 Earnings

Earnings Call

You can ask Aime

AVTR

AVTR fundamentals

AVTR Q4 2025 Earnings

Earnings Call

AVTR Earnings Call Summary for Q4/20258:00 AM on Feb 11, 2026

AVTR Earnings Call Summary for Q3/20258:00 AM on Oct 29, 2025

AVTR Earnings Call Summary for Q2/20258:00 AM on Aug 1, 2025

AVTR Earnings Call Summary for Q1/20258:00 AM on Apr 25, 2025

AVTR Earnings Call Summary for Q4/20248:00 AM on Feb 7, 2025

You can ask Aime